Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04733989 · ClinicalTrials.gov registry record
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
A clinical trial, sponsored by GAP Innovations, PBC.
- Completed
- Registry status
- 1,002
- Enrollment target
NCT04733989 is a clinical trial that has completed, run by GAP Innovations, PBC. The registered enrollment target is 1,002 participants.
The verdict
NCT04733989 has completed, sponsored by GAP Innovations, PBC.
- COMPLETED
- Registry status
- 1,002 participants
- Enrollment target
Study Summary
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood amyloid-beta, p-tau, and neurofilament biomarker levels and amyloid-beta levels identified through brain amyloid PET images. Blood collected will also be genetically sequenced to gain insights about genes and brain amyloid. The Bio-Hermes study will include 1,000 volunteers over the age of 60 screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, and includes an endpoint enrollment requirement of 200 participants from underrepresented minority populations.
Interventions
- OTHER Biomarker Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04733989
The ClinicalTrials.gov registry entry for NCT04733989 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GAP Innovations, PBC, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biomarker Data Collection is the first listed.
NCT04733989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04733989 about?
NCT04733989 is a clinical study titled "A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)". The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood amyloid-beta, p-tau, and neurofilament biomarker levels and amyloid-beta levels ide...
What is the current status of trial NCT04733989?
This trial is currently completed. The enrollment target is 1,002 participants. The study started on 2021-04-21. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT04733989?
The interventions under investigation include: Biomarker Data Collection (OTHER).
Who is sponsoring clinical trial NCT04733989?
This trial is sponsored by GAP Innovations, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.